Oral SERD field expands — bar for differentiation rises

As targeted protein degradation gains momentum, oral SERDs are emerging as one of its most advanced proving grounds.

With at least 11 readouts expected this year in estrogen receptor-positive breast cancer, the growing pipeline of selective estrogen receptor degraders (SERDs) will begin to separate on depth of ER pathway suppression and efficacy across treatment settings. The trade-offs between different degrader modalities should also come into better focus...